1-3 of 3
Satya Medicherla
Close
Sort by
Journal Articles

From in silico to in Vitro to In Vivo : Increasing Megakaryocytes to Treat Thrombocytopenia

Alejandra Macias, Mauricio Cortes, Na An, Na Li, Timothy Fulton, Allison Simpson, Samuel Miller, Sunny Sun, Doris Fu, Juan Garcia, Satya Medicherla, Scott Steelman, Atli Thorarensen, Matthew Goddeeris, Sriram Krishnamoorthy
Journal: Blood
Blood (2023) 142 (Supplement 1): 5580.
https://doi.org/10.1182/blood-2023-190250
Published: 2023
Journal Articles

Inhibition of p38α MAPK Reduces Tumor Burden, Prevents the Development of Myeloma Bone Disease, and Increases Survival in the 5T2 and 5T33 Murine Models of Myeloma.

Karin Vanderkerken, PhD, Satya Medicherla, PhD, Les Coulton, PhD, Benjamin Van Camp, MD, PhD, Andy Protter, PhD, Linda Higgins, PhD, Eline Menu, PhD, Peter Croucher, PhD
Journal: Blood
Blood (2006) 108 (11): 3436.
https://doi.org/10.1182/blood.V108.11.3436.3436
Published: 2006
Journal Articles

SCIO-469, a Potent and Selective Inhibitor of p38a MAPK, Normalizes the Bone Marrow Microenvironment and Inhibits Multiple Myeloma Cell Proliferation in In Vitro and In Vivo Models.

Aaron N. Nguyen, PhD, Mamatha Reddy, MS, Margaret Henson, MS, Elizabeth G. Stebbins, PhD, Gilbert O’Young, BS, Jing Y. Ma, MD, Edwin Haghnazari, PhD, Ann M. Kapoun, PhD, Satya Medicherla, PhD, Andy Protter, PhD, Tony A. Navas, PhD, Linda S. Higgins, PhD
Journal: Blood
Blood (2004) 104 (11): 1501.
https://doi.org/10.1182/blood.V104.11.1501.1501
Published: 2004